Short Interest in BriaCell Therapeutics Corp. (NASDAQ:BCTX) Rises By 245.7%

BriaCell Therapeutics Corp. (NASDAQ:BCTX) was the target of a large increase in short interest in December. As of December 15th, there was short interest totalling 2,380,000 shares, an increase of 245.7% from the November 30th total of 688,400 shares. Currently, 6.0% of the company’s stock are short sold. Based on an average trading volume of 2,490,000 shares, the days-to-cover ratio is presently 1.0 days.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and set a $15.00 price objective on shares of BriaCell Therapeutics in a report on Thursday, December 12th.

Hedge Funds Weigh In On BriaCell Therapeutics

A hedge fund recently bought a new stake in BriaCell Therapeutics stock. Vontobel Holding Ltd. acquired a new stake in BriaCell Therapeutics Corp. (NASDAQ:BCTX) in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 80,000 shares of the company’s stock, valued at approximately $99,000. Vontobel Holding Ltd. owned 0.44% of BriaCell Therapeutics at the end of the most recent reporting period. Institutional investors and hedge funds own 15.42% of the company’s stock.

BriaCell Therapeutics Stock Up 3.9 %

NASDAQ BCTX traded up $0.02 on Friday, reaching $0.56. The company had a trading volume of 517,645 shares, compared to its average volume of 1,625,234. The stock has a market capitalization of $24.22 million, a P/E ratio of -0.48 and a beta of 1.46. The company’s fifty day moving average is $0.76 and its 200 day moving average is $0.82. BriaCell Therapeutics has a 52-week low of $0.46 and a 52-week high of $5.97.

BriaCell Therapeutics (NASDAQ:BCTX) last released its quarterly earnings results on Monday, December 16th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.14). On average, research analysts expect that BriaCell Therapeutics will post -1.01 EPS for the current year.

About BriaCell Therapeutics

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.